Elsevier

Clinical Lymphoma

Volume 3, Issue 2, September 2002, Pages 105-110
Clinical Lymphoma

Original Contribution
Cytomegalovirus Viremia During Campath-1H Therapy for Relapsed and Refractory Chronic Lymphocytic Leukemia and Prolymphocytic Leukemia

https://doi.org/10.3816/CLM.2002.n.016Get rights and content

Abstract

Campath-1H is effective therapy for patients with relapsed and refractory chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL), but it is associated with profound lymphopenia and deficiencies in cell-mediated immunity. We report the incidence of cytomegalovirus (CMV) viremia in 34 patients treated with Campath-1H for relapsed or refractory CLL and PLL. All patients received infection prophylaxis during therapy and continuing for at least 2 months following Campath-1H. Five patients (15%) developed CMV viremia at a median of 28 days (range, 20–30 days) after the first dose of Campath-1H. The median CMV viral load was 860/mL (range, 420–2100/mL), as determined by quantitative plasma polymerase chain reaction (PCR). All 5 patients had a temperature > 38.5°C, normal chest radiographs, normal liver function tests, and negative bacterial blood cultures with no clinical evidence of CMV disease at the time of presentation with CMV viremia. The median absolute neutrophil count (ANC) was 740/μL (range, 340-1600/μL), and the median absolute lymphocyte count (ALC) was 16/μL (range, 11–169/μL) for the 5 patients at the time of CMV viremia. All 5 patients received ganciclovir therapy followed by prompt fever resolution and clearance of CMV viremia by plasma PCR. By univariate regression analysis, the following were not risk factors for CMV viremia: age, number of prior regimens, prior rituximab therapy, prior splenectomy, modified Rai stage at Campath-1H therapy (low/intermediate vs. high), ANC, and ALC; although, there was a trend towards significance for prior rituximab therapy (P = 0.07). Cytomegalovirus viremia may be a significant infectious complication during Campath-1H therapy and should be investigated further in future studies.

References (34)

  • A Osterborg et al.

    Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia

    Br J Haematol

    (1996)
  • M Uppenkamp et al.

    Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non- Hodgkin's lymphomas: a multicenter phase I/II study

    Ann Hematol

    (2002)
  • F Willis et al.

    The effect of treatment with Campath- 1H in patients with autoimmune cytopenias

    Br J Haematol

    (2001)
  • JD Issacs et al.

    Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia

    Arthritis Rheum

    (2001)
  • SC Tang et al.

    Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma

    Leuk Lymphoma

    (1996)
  • JA Zaia

    Cytomegalovirus Infections

  • DR Cox

    Regression models and life tables

    J R Stat Soc

    (1972)
  • Cited by (63)

    • How I manage infection risk and prevention in patients with lymphoid cancer

      2022, Blood
      Citation Excerpt :

      She received treatment with ganciclovir and was transitioned to valganciclovir once the diarrhea resolved. CMV reactivation is common among patients with lymphoid malignancies, including those who receive therapy with brentuximab vedotin, and occurs most frequently between 3 and 6 weeks after initiation of therapy when T-cell counts reach a nadir.13-16 The most relevant risk factors seem to be advanced disease, poor performance status, CD34+ selected autografts, total body irradiation, and treatment with alemtuzumab, fludarabine, bortezomib, rituximab, or high-dose steroids.17

    • Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation

      2021, Blood
      Citation Excerpt :

      The CMV serostatus of the donor and recipient remain the most important predictors of CMV disease after HCT, with seropositive recipients at the highest risk, seronegative recipients with seropositive donors at intermediate risk, and seronegative recipients with seronegative donors at the lowest risk.4 The chemotherapy regimen used for conditioning before HCT also affects the risk of CMV reactivation and disease, with the use of rabbit anti-thymocyte globulin,8 alemtuzumab,8-11 or reduced intensity conditioning4 conferring higher risk. The use of cord blood grafts12 and the development of graft-versus-host disease (GVHD) after HCT4 are also associated with higher risks for CMV reactivation and disease.

    • Lung infections after cancer chemotherapy

      2008, The Lancet Oncology
      Citation Excerpt :

      Moreover, pneumonia is particularly common in patients with lymphoma or acute leukaemia.39 Risk of infection is increased by: use of aggressive T-lymphocytotoxic chemotherapy (such as in induction of acute leukaemia with cytarabine, fludarabine, or high-dose cyclophosphamide); treatment with T-cell suppressors (such as methotrexate or corticosteroids);39 or by treatment with T-cell depleting agents such as alemtuzumab, rituximab, or fludarabine.40,41 Diagnosis of cytomegalovirus pneumonia is challenging because it depends on virus detection in samples of lung tissue by use of immunohistochemical staining, histopathological assessment for viral inclusions, or culture.

    • Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

      2008, Blood
      Citation Excerpt :

      Thus, most patients receive trimethoprim-sulfa twice daily 3 times a week and daily anti-herpes virus treatment with acyclovir, famciclovir, or valaciclovir. Since the introduction of alemtuzumab therapy into the treatment armamentarium for CLL, it has been recognized that cytomegalovirus (CMV) reactivation may occur in patients receiving this antibody, presumably because of the extensive T-cell depletion associated with the therapy.4,5 A review of 78 patients with chronic lymphocytic disorders receiving alemtuzumab at M. D. Anderson Cancer Center indicated that the symptomatic reactivation rate was 20%.6

    View all citing articles on Scopus
    View full text